IP Library › Granted Patent US 12,559,754
Granted Patent B2
US 12,559,754 · App. 18/518,069 · Granted Feb 24, 2026

Composition for regulating production of interfering ribonucleic acid

Inventor: Bradley G. Thompson (Calgary, CA)
Assignee: Wyvern Pharmaceuticals Inc.
C12N15/1137C12N15/86C12N2310/141C12N2750/14143C12Y207/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,559,754
App. No.
18/518,069
Granted
Feb 24, 2026
Kind
B2
Abstract

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a kinase.

Claims (2)

1 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO: 2.

2 . The composition of claim 1 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2025
From: THOPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072073/0434 →
Continuity (1)
Related Publication 20250163422A1 · May 22, 2025
References Cited (40)
US 11085055B2 · Mallol Dominguez · 2021 [cited by examiner]
US 11162102B2 · Minshull · 2021 [cited by examiner]
US 11530423B1 · Thompson · 2022 [cited by applicant]
US 11873505B2 · Thompson · 2024 [cited by applicant]
US 12018274B2 · Thompson · 2024 [cited by applicant]
US 12134770B1 · Thompson · 2024 [cited by applicant]
US 20200362344A1 · Minshull et al. · 2020 [cited by applicant]
US 20240026377A1 · Thompson · 2024 [cited by applicant]
CA 2721333A1 · 2009 [cited by examiner]
Bottoni A, et al., Blood. Dec. 29, 2016; 128(26):3101-3112 (Year: 2016). [cited by examiner]
Christensen et al. pp. 1-10, Frontiers in Neural Circuits, Article 16, vol. 3, Year 2010 (Year: 2010). [cited by examiner]
Bofill-De Ros X, Gu S. Guidelines for the optimal design of miRNA-based shRNAs. Methods. Jul. 1, 2016;103:157-66 (Year: 2016). [cited by examiner]
Denzler R et al., Mol Cell. Nov. 3, 2016;64(3):565-579 (Year: 2016). [cited by examiner]
Fiona T van den Berg, et al., Molecular Therapy—Nucleic Acids, vol. 5, 2016 (Year: 2016). [cited by examiner]
Bottoni A, et al., Blood. Dec. 2, 20169;128(26):3101-3112 (Year: 2016). [cited by examiner]
O'Brien, et al., Aug. 3, 2018, Front Endocrinol (Lausanne), 9:402, p. 1-12; Fig. 1; p. 2, “Biogenesis of miRNAs” (Year: 2018). [cited by examiner]
Gorski, S., Vogel, J. & Doudna, J., Nat Rev Mol Cell Biol 18, 215-228 (2017) (Year: 2017). [cited by examiner]
Brutons Tyrosine Kinase Genbank Sequence (Year: 2023). [cited by examiner]
Lam et al. 2015. Molec. Ther. Nuc. Ac. 4:e252 (Year: 2015). [cited by examiner]
Ying et al. 2008. Mol. Biotechnol. 38:257-268 (Year: 2008). [cited by examiner]
Tritscheler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506. [cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.” Oncotarget 11.44 (2020): 4016. [cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253. [cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494. [cited by applicant]
NCBI search results for SEQ ID No. 5 (2024). [cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023). [cited by applicant]
GenBank FLT3 Sequence (2024). [cited by applicant]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010). [cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023). [cited by applicant]
NCBI Nucleotide Sequence for PARP, search performed Dec. 26, 2024 (2024). [cited by applicant]
GenBank EGFR Sequence (2023). [cited by applicant]
GenBank EGF Sequence (2023). [cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675. [cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery”. Nat Rev Drug Discov. May 2019; 18(5):358-378. (Year: 2019). [cited by applicant]
Pagliuca ( et al. 2013. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 32:4806-4813) (Year: 2013). [cited by applicant]
Fattore ( et al. 2016. miR-579-3p controls melanoma progression and resistance to target therapy. PNAS 113 [34]:E5005-E5013) ( Year: 2016). [cited by applicant]
Origene (2024. Product datasheet for SC207797 B Raf [BRAF] [NM_004333] Human 3′ UTR Clone. Rockville, MD: Origene) (Year:2024). [cited by applicant]
NCBI ( [cited by applicant]
MiRbase (2025. “miR-143” and “miR-145”, and “miR-579-3p”. Available online at miRbase.org. Accessed on May 16, 2025) (Year: 2025). [cited by applicant]
[cited by applicant]